EyePoint, Inc. - Common Stock NASDAQ
1 scored calls · 1 channels · first tracked 17 Aug 2026
Last 12 months · 1 buying · 0 selling
Bloomberg Television
Buy
Calls
1
Return
+9.2%
Show calls
THE MAIN THING HERE WAS CANCER CUT THE RATING ON THE COMPANY FROM NEUTRAL TO OVERWEIGHT SAYING THE TRIAL MESS WAS A SCENARIO SHOWING WE HAVE NOT EVEN CONTEMPLATED IT IN OUR BOLD BEAR BASE CASE SCENARIO ANALYSIS IN OUR RECENT INITIATION.
